These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18525066)

  • 1. Exploring the pharmacotherapeutic options for treating type 2 diabetes.
    Kruger DF
    Diabetes Educ; 2008; 34 Suppl 3():60S-65S. PubMed ID: 18525066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating diabetes with incretin hormones - clinical experience.
    Handelsman Y
    Pediatr Endocrinol Rev; 2008 Jun; 5(4):897-903. PubMed ID: 18552752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL
    Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs.
    Efendic S; Alvarsson M; Brismar K; Wagner H
    Acta Physiol (Oxf); 2008 Jan; 192(1):117-25. PubMed ID: 18171434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies: mimetics versus protease inhibitors.
    Brubaker PL
    Trends Endocrinol Metab; 2007 Aug; 18(6):240-5. PubMed ID: 17629492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes].
    Scheen AJ; Radermecker RP; Philips JC; Paquot N
    Rev Med Suisse; 2007 Aug; 3(122):1884, 1886-8. PubMed ID: 17896662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings.
    Collins FM
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S460-71. PubMed ID: 12408409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Incretins in the treatment of diabetes].
    Bulum T; Smircić-Duvnjak L; Car N; Metelko Z
    Lijec Vjesn; 2008; 130(7-8):195-200. PubMed ID: 18979908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
    DeFronzo RA
    Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for type 2 diabetes mellitus.
    Elson DF; Meredith M
    WMJ; 1998 Mar; 97(3):49-54. PubMed ID: 9540451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of blood glucose in type 2 diabetes mellitus.
    Ripsin CM; Kang H; Urban RJ
    Am Fam Physician; 2009 Jan; 79(1):29-36. PubMed ID: 19145963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK; Holst JJ; Vilsbøll T
    IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of beta-cell management in type 2 diabetes.
    Standl E
    Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the role of incretin mimetic therapy in the management of type 2 diabetes.
    Unger J; Nadeau DA
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.